



HANGZHOU JIUYUAN GENETIC BIOPHARMACEUTICAL CO., LTD.

杭州九源基因生物醫藥股份有限公司

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

Stock code : 2566

**2025**

INTERIM REPORT



# CONTENT

|    |                                                                                           |
|----|-------------------------------------------------------------------------------------------|
| 2  | Definitions                                                                               |
| 6  | Corporate Information                                                                     |
| 8  | Financial Summary                                                                         |
| 9  | Management Discussion and Analysis                                                        |
| 18 | Corporate Governance and Other Information                                                |
| 26 | Interim Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income |
| 27 | Interim Condensed Consolidated Statement of Financial Position                            |
| 29 | Interim Condensed Consolidated Statement of Changes in Equity                             |
| 30 | Interim Condensed Consolidated Statement of Cash Flows                                    |
| 32 | Notes to Interim Condensed Consolidated Financial Information                             |





## Definitions

In this interim report, unless the context otherwise requires, the following terms have the following meanings. These terms and their definitions may not correspond to any industry standard definition and may not be directly comparable to similarly titled terms adopted by other companies operating in the same industries as the Company.

|                                            |                                                                                                                                                                                                                                                                                                                                        |
|--------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| "Articles of Association"                  | the articles of association of the Company, as amended, supplemented or otherwise modified from time to time                                                                                                                                                                                                                           |
| "Audit Committee"                          | the audit committee of the Board                                                                                                                                                                                                                                                                                                       |
| "Board"                                    | the board of directors of the Company                                                                                                                                                                                                                                                                                                  |
| "Business Day(s)"                          | any day on which the Stock Exchange is open for the business of dealing in securities                                                                                                                                                                                                                                                  |
| "CDE"                                      | Center for Drug Evaluation of NMPA (國家藥品監督管理局藥品審評中心), a division of the NMPA mainly responsible for review and approval of IND and NDA                                                                                                                                                                                                 |
| "CG Code"                                  | Corporate Governance Code set out in Appendix C1 to the Listing Rules                                                                                                                                                                                                                                                                  |
| "Chairman" or "Chairman of the Board"      | the chairman of the Board                                                                                                                                                                                                                                                                                                              |
| "China" or the "PRC"                       | the People's Republic of China, but for the purpose of this interim report and for geographical reference only, unless the context otherwise requires, excludes Hong Kong, the Macau Special Administrative Region of the PRC and Taiwan                                                                                               |
| "Companies Ordinance"                      | the Companies Ordinance (Chapter 622 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time                                                                                                                                                                                                       |
| "Company," "our Company," or "the Company" | Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (杭州九源基因生物醫藥股份有限公司) (previously known as Hangzhou Jiuyuan Gene Engineering Co., Ltd. (杭州九源基因工程股份有限公司)), a limited liability company established under the laws of the PRC on December 31, 1993 and converted into a joint stock company with limited liability on December 5, 2023 |
| "Corresponding Period"                     | for the six months ended June 30, 2024                                                                                                                                                                                                                                                                                                 |

## Definitions

|                                               |                                                                                                                                                                                                                                    |
|-----------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| "CQFE"                                        | Corporacion Quimico-farmaceutica Esteve, Sociedad Anónima, a corporation organized under the laws of the Kingdom of Spain on June 6, 1986                                                                                          |
| "Director(s)"                                 | the director(s) of our Company                                                                                                                                                                                                     |
| "Domestic Share(s)"                           | ordinary share(s) in the share capital of the Company with a nominal value of RMB1.00 each, which is/are subscribed for and paid up in Renminbi by domestic investors and are not listed or traded on any stock exchange           |
| "Global Offering"                             | the offer of Shares for subscription as described in the Prospectus                                                                                                                                                                |
| "Group," "our Group,"<br>"we," "us," or "our" | the Company and its subsidiaries from time to time                                                                                                                                                                                 |
| "H Share(s)"                                  | ordinary share(s) in the share capital of the Company with a nominal value of RMB1.00 each, which are traded in Hong Kong dollars and listed on the Stock Exchange                                                                 |
| "Hangzhou Huasheng"                           | Hangzhou Huasheng Pharmaceutical Group Co., Ltd. (杭州華昇醫藥集團有限公司, formerly known successively as 杭州華東醫藥集團控股有限公司, 杭州華東醫藥集團投資有限公司 and 杭州博華投資有限公司), a limited liability company established under the laws of the PRC on March 25, 2002 |
| "Hangzhou Investment"                         | Hangzhou Investment Holdings Co., Ltd. (杭州市金融投資集團有限公司, formerly known as 杭州市投資控股有限公司), a limited liability company established under the laws of the PRC on August 28, 1997                                                        |
| "Heda HK"                                     | Heda Jinyuan (HK) Co., Limited (和達金源(香港)有限公司), a limited company incorporated under the laws of Hong Kong in July 2024                                                                                                             |
| "Highland Pharma"                             | Highland Pharma Limited, a private company limited by shares incorporated under the laws of Ireland on January 31, 2003                                                                                                            |
| "H Share Registrar"                           | Computershare Hong Kong Investor Services Limited                                                                                                                                                                                  |
| "HK\$" or "HKD"                               | Hong Kong dollars and cents respectively, the lawful currency of Hong Kong                                                                                                                                                         |
| "Hong Kong" or "HK"                           | the Hong Kong Special Administrative Region of the PRC                                                                                                                                                                             |



## Definitions

|                                        |                                                                                                                                                                                                                        |
|----------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| “Huadong Medicine”                     | Huadong Medicine Co., Ltd. (華東醫藥股份有限公司), a limited liability company established under the laws of the PRC on March 31, 1993, the A shares of which are listed on the Shenzhen Stock Exchange (stock code: 000963.SZ)  |
| “Listing Rules”                        | the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended, supplemented or otherwise modified from time to time                                                             |
| “Listing”                              | the listing of the H Shares on the Main Board of the Stock Exchange                                                                                                                                                    |
| “Listing Date”                         | November 28, 2024, on which the H Shares were listed and dealings in the H Shares first commenced on the Stock Exchange                                                                                                |
| “Model Code”                           | the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 to the Listing Rules                                                                                               |
| “Nanbeiju”                             | Hangzhou Nanbeiju Enterprise Management Partnership (杭州南北聚企業管理合夥企業), a limited liability partnership established under the laws of the PRC on July 21, 2023, one of the employee shareholding platforms of the Company |
| “Nanjing King-Friend”                  | Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. (南京健友生化製藥股份有限公司)                                                                                                                                              |
| “Nomination Committee”                 | the nomination committee of our Board                                                                                                                                                                                  |
| “PRC Company Law”                      | Company Law of the PRC (《中華人民共和國公司法》), as amended, supplemented or otherwise modified from time to time                                                                                                                |
| “Prospectus”                           | the prospectus of the Company dated November 20, 2024                                                                                                                                                                  |
| “R&D”                                  | research and development                                                                                                                                                                                               |
| “Remuneration and Appraisal Committee” | the remuneration and appraisal committee of our Board                                                                                                                                                                  |
| “Reporting Period”                     | for the six months ended June 30, 2025                                                                                                                                                                                 |
| “RMB” or “Renminbi”                    | the lawful currency of the PRC                                                                                                                                                                                         |
| “SFO”                                  | the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong (as amended, supplemented or otherwise modified from time to time)                                                                          |

## Definitions

|                                                   |                                                                                                                                                                                                                                             |
|---------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| "Share(s)"                                        | ordinary share(s) in the share capital of the Company with a nominal value of RMB1.00 each, comprising the Unlisted Share(s) and H Share(s)                                                                                                 |
| "Shareholder(s)"                                  | shareholder(s) of the Company                                                                                                                                                                                                               |
| "Stock Exchange" or<br>"Hong Kong Stock Exchange" | The Stock Exchange of Hong Kong Limited, a wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited                                                                                                                              |
| "Supervisor(s)"                                   | member(s) of the Supervisory Committee                                                                                                                                                                                                      |
| "Supervisory Committee"                           | the supervisory committee of the Company                                                                                                                                                                                                    |
| "Tax Measures"                                    | Announcement of the State Taxation Administration on Issuing the Measures for Non-resident Taxpayers' Enjoyment of Treaty Benefits (Announcement No. 35 [2019] of the State Taxation Administration)                                        |
| "treasury Shares"                                 | the meaning as defined under the Listing Rules                                                                                                                                                                                              |
| "T2DM"                                            | type 2 diabetes mellitus, a metabolic disorder marked by insulin resistance and relative insulin deficiency, often associated with obesity and lifestyle factors                                                                            |
| "U.S." or "United States"                         | the United States of America, its territories and possessions, any State of the United States, and the District of Columbia                                                                                                                 |
| "Unlisted Foreign Share(s)"                       | ordinary share(s) issued by the Company with a nominal value of RMB1.00 each which is/are subscribed for and paid for in currency other than RMB by foreign investors and not listed on any stock exchange                                  |
| "Unlisted Shares"                                 | Domestic Shares and Unlisted Foreign Shares                                                                                                                                                                                                 |
| "US\$"                                            | United States dollar, the lawful currency of the United States                                                                                                                                                                              |
| "Zhejiang Wangxin"                                | Zhejiang Wangxin Technology Venture Capital Co., Ltd. (浙江網新科技創投有限公司), a limited liability company established under the laws of the PRC on June 3, 2010, which is a wholly-owned subsidiary of Insignia Technology Co., Ltd. (浙大網新科技股份有限公司) |
| "Zhongmei Huadong"                                | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (杭州中美華東製藥有限公司), a limited liability company established under the laws of the PRC on December 31, 1992, which is a wholly-owned subsidiary of Huadong Medicine                           |
| "%"                                               | per cent                                                                                                                                                                                                                                    |

In this interim report, unless otherwise indicated, the terms "associate", "associated corporation", "connected person", "subsidiary" and "substantial shareholder" shall have the meanings given to such terms in the Listing Rules.



# Corporate Information

## BOARD

### Executive Director

Mr. Fu Hang (傅航)

*(Chairman of the Board and general manager)*

Mr. Zhou Wei (周偉)

### Non-executive Directors

Ms. Ma Honglan (馬紅蘭)

Mr. Wu Shihang (吳詩航)

Mr. Albert Esteve Cruella

Mr. Fei Junjie (費俊傑)

### Independent Non-executive Directors

Mr. Zhou Zhihui (周智慧)

Ms. Ho Mei Yi (何美儀)

Dr. Zhou Demin (周德敏)

## SUPERVISORS

Mr. Ye Jiancai (葉建才)

Mr. Xu Feihu (徐飛虎)

Ms. Zhao Fei (趙飛)

## REGISTERED OFFICE, HEAD OFFICE AND PRINCIPAL PLACE OF BUSINESS IN THE PRC

No. 23, Eighth Street  
Baiyang Street, Qiantang District  
Hangzhou, Zhejiang Province  
PRC

## PRINCIPAL PLACE OF BUSINESS IN HONG KONG REGISTERED UNDER PART 16 OF THE COMPANIES ORDINANCE

46/F, Hopewell Centre  
183 Queen's Road East  
Wan Chai  
Hong Kong

## H SHARE REGISTRAR

### Computershare Hong Kong Investor Services Limited

Shops 1712-1716, 17th Floor

Hopewell Centre

183 Queen's Road East

Wan Chai

Hong Kong

## COMPLIANCE ADVISER

### Maxa Capital Limited

Unit 2602, 26/F, Golden Centre

188 Des Voeux Road Central, Sheung Wan

Hong Kong

## JOINT COMPANY SECRETARIES

Ms. Huang Xiu (黃秀)

Ms. Ho Wing Nga (何詠雅)

*(fellow of both The Hong Kong Chartered Governance  
Institute and The Chartered Governance Institute)*

## AUTHORIZED REPRESENTATIVES

Mr. Fu Hang (傅航)

Ms. Ho Wing Nga (何詠雅)

## AUDIT COMMITTEE

Mr. Zhou Zhihui (周智慧) *(Chairman)*

Ms. Ho Mei Yi (何美儀)

Dr. Zhou Demin (周德敏)

## NOMINATION COMMITTEE

Ms. Ho Mei Yi (何美儀) *(Chairwoman)*

Mr. Fu Hang (傅航)

Dr. Zhou Demin (周德敏)

# Corporate Information

## REMUNERATION AND APPRAISAL COMMITTEE

Dr. Zhou Demin (周德敏) (*Chairman*)

Mr. Zhou Wei (周偉)

Mr. Zhou Zihui (周智慧)

## STOCK CODE

2566

## PRINCIPAL BANKS

### China Merchants Bank

#### Hangzhou Shenlan Sub-branch

1-2F, No. 332 Wangjiang East Road Shangcheng District

Hangzhou, Zhejiang Province

PRC

### Bank of China

#### Hangzhou Qiantang New District Sub-branch

No. 17, No. 3 Street, Baiyang Street

Qiantang District

Hangzhou, Zhejiang Province

PRC

### China CITIC Bank

#### Hangzhou Economic and

#### Technological Development Zone Sub-branch

No. 2, Science and Technology Park Road, Baiyang Street

Qiantang District

Hangzhou, Zhejiang Province

PRC

## AUDITOR

### Ernst & Young

*Certified Public Accountants*

*Registered Public Interest Entity Auditor*

27/F, One Taikoo Place

979 King's Road

Quarry Bay

Hong Kong

## LEGAL ADVISERS TO THE COMPANY

*As to Hong Kong law:*

### Cooley HK

35/F, Two Exchange Square

8 Connaught Place

Central

Hong Kong

*As to PRC law:*

### Zhejiang T&C Law Firm

11/F, Block A, Dragon Century Square No. 1 Hangda Road

Hangzhou, Zhejiang

PRC

## COMPANY'S WEBSITE

[www.china-gene.com](http://www.china-gene.com)



# Financial Summary

|                                                              | Six months ended June 30, |           |
|--------------------------------------------------------------|---------------------------|-----------|
|                                                              | 2025                      | 2024      |
|                                                              | RMB'000                   | RMB'000   |
|                                                              | (Unaudited)               | (Audited) |
| Results of operations:                                       |                           |           |
| Revenue                                                      | 638,778                   | 702,360   |
| Gross profit                                                 | 525,219                   | 540,560   |
| Profit for the period                                        | 90,174                    | 105,348   |
| Net profit attributable to shareholders of the parent        | 90,174                    | 105,348   |
| Profitability:                                               |                           |           |
| Gross profit margin                                          | 82.2%                     | 77.0%     |
| Net profit margin attributable to shareholders of the parent | 14.1%                     | 15.0%     |
| Earnings per share (RMB):                                    |                           |           |
| Basic and diluted                                            | 0.37                      | 0.53      |

# Management Discussion and Analysis

## BUSINESS REVIEW

### Overview

As of June 30, 2025, the Company achieved total revenue of RMB638.8 million, representing a period-on-period decrease of 9.1%. Profit for the period amounted to RMB90.2 million, representing a period-on-period change of -14.4%. The slight decline in total revenue for the first half of the year was mainly due to a combination of internal and external factors. With respect to pharmaceutical industry policies, with the continued deepening of Diagnosis Related Groups/Disease Severity and Intervention Complexity Points (DRG/DIP) reforms, national medical insurance cost control efforts have been strengthened, and external-use drugs outside of centralized procurement are facing certain pressures. Public medical institutions are required to further rebalance medical insurance cost control indicators and the cost-effectiveness of pharmaceuticals. The promotion of pharmaceutical price reform and governance has led to a consensus on the rules for listing drug prices, and provincial-level price linkage has resulted in price adjustments for certain products. At the corporate level, in order to strengthen cash collection, the sales model of some products was adjusted from direct sales to commercial distribution. In the first half of the year, the Company's name change required some hospital products to undergo renewed market access procedures, which had a certain impact on the Company's performance.

During the Reporting Period, the sales volume of the Company's orthopedics products increased by more than 10% period-on-period, and hospital penetration rate continued to improve. Focusing on the Company's annual business objectives, we implemented differentiated commercial policies with an emphasis on stabilizing the existing market and cultivating incremental markets, striving to achieve steady growth in annual business revenue. For the existing market, we continued to adhere to professional academic promotion as the guiding principle, and organized various levels of orthopedic product exchanges, academic salons, and inter-hospital exchange meetings; improved the professional competence of business personnel to enhance the stability of orthopedic products in the hospital market; strengthened the full-cycle management of orthopedic products, and in addition to orthopedic treatment services, expanded services such as postoperative rehabilitation and postoperative care. For incremental markets, we expanded the team to increase coverage of previously untapped county-level hospitals; actively organized and participated in national and regional academic conferences, provided in-depth training to improve the technical level of grassroots doctors, and promoted awareness of the Company's orthopedic products; actively promoted comprehensive inclusion in provincial medical insurance catalogs to enhance product competitiveness.

# Management Discussion and Analysis

## Product Pipeline

By making full use of our existing technology platform, we are committed to developing innovative products in the fields of metabolism, orthopedics, oncology, and hematology. As of the date of this report, the Company has laid out a rich R&D pipelines in the aforementioned fields, including multiple innovative drugs, biosimilars, and biopharmaceutical-device combination products.

The table below sets forth the therapeutic targets, disease areas, and development status of our product candidates as of the date of this report:

| Pipeline for Product Candidates <sup>(1)</sup> |                                                    |                         |                                    |                        |                                                         |                        |                            |                        |                         |                           |                        |     |                   |                                        |                     |                |                                                            |
|------------------------------------------------|----------------------------------------------------|-------------------------|------------------------------------|------------------------|---------------------------------------------------------|------------------------|----------------------------|------------------------|-------------------------|---------------------------|------------------------|-----|-------------------|----------------------------------------|---------------------|----------------|------------------------------------------------------------|
| Project Name                                   | Product Name                                       | Product Type            | Expected Classification            | Dosage Form            | Target/MoA                                              | Indications            | Pre-clinical               | IND                    | Phase I                 | Phase II                  | Phase III              | NDA | Commercialization | Next Milestone (Expected Time)         | Competent Authority | Source         | Expiry Date of the Originator Drug's Patent <sup>(5)</sup> |
| Metabolism                                     |                                                    |                         |                                    |                        |                                                         |                        |                            |                        |                         |                           |                        |     |                   |                                        |                     |                |                                                            |
| JY29-2<br>吉优泰®<br>Jiyoutai                     | Semaglutide <sup>(2)</sup>                         | Peptide                 | Biosimilar <sup>(3)</sup>          | Subcutaneous injection | Glucagon-like peptide-1 (GLP-1) receptor agonist        | T2DM                   | <div><div></div></div>     |                        |                         | Filed NDA on Mar 24, 2024 |                        |     |                   | Approval from NMPA (2025H2)            | NMPA                | Self-developed | Mar 20, 2026                                               |
| JY29-2<br>吉可奈®<br>Jikeqin <sup>(2)</sup>       |                                                    |                         |                                    |                        |                                                         |                        |                            |                        |                         |                           |                        |     |                   | File NDA (2026H1)                      | NMPA                | Self-developed | Mar 20, 2026                                               |
| JY29-2 (Oral)                                  |                                                    |                         |                                    | Tablets                |                                                         | Obesity and overweight | <div><div></div></div>     |                        |                         |                           |                        |     |                   | File IND application (2027)            | NMPA                | Self-developed | Mar 20, 2026                                               |
| JY54                                           |                                                    |                         |                                    | Amylin analog          |                                                         | Peptide                | Category I innovative drug | Subcutaneous injection | DACRAS receptor agonist | Obesity and overweight    | <div><div></div></div> |     |                   |                                        |                     |                |                                                            |
| JY54-2                                         | Amylin analog-2                                    | Peptide                 | Category I innovative drug         | Subcutaneous injection | DACRAS receptor agonist                                 | Obesity and overweight | <div><div></div></div>     |                        |                         |                           |                        |     |                   | File IND application (2026Q2)          | NMPA                | Self-developed | N/A                                                        |
| Orthopedics                                    |                                                    |                         |                                    |                        |                                                         |                        |                            |                        |                         |                           |                        |     |                   |                                        |                     |                |                                                            |
| JY23                                           | multipotent biological bone containing rhBMP-2     | Drug-device combination | Drug-device combination            | Bone graft             | Bone Morphogenetic Protein and Biomaterials             | Bone repair            | <div><div></div></div>     |                        |                         |                           |                        |     |                   | File registration materials (2026H1)   | NMPA                | Self-developed | N/A                                                        |
| JY23-2                                         | Injectable rhBMP-2-integrated bone repair material | Drug-device combination | Innovative drug-device combination | Bone graft             | Bone Morphogenetic Protein and Biomaterials             | Bone repair            | <div><div></div></div>     |                        |                         |                           |                        |     |                   | Conduct clinical study (2027)          | NMPA                | Self-developed | N/A                                                        |
| Oncology                                       |                                                    |                         |                                    |                        |                                                         |                        |                            |                        |                         |                           |                        |     |                   |                                        |                     |                |                                                            |
| JY47                                           | SIRPα monoclonal antibody                          | Monoclonal antibody     | Category I innovative biologics    | Intravenous injection  | CD47-SIRPα inhibitor                                    | Solid tumors           | <div><div></div></div>     |                        |                         |                           |                        |     |                   | Phase I clinical trial (2025)          | NMPA                | Self-developed | N/A                                                        |
| JY43                                           | Daratumumab                                        | Monoclonal antibody     | Biosimilar <sup>(3)</sup>          | Intravenous injection  | CD38 inhibitor                                          | Multiple myeloma       | <div><div></div></div>     |                        |                         |                           |                        |     |                   | Phase I clinical trial (2025 or later) | NMPA                | Self-developed | Mar 22, 2026                                               |
| JY43-2                                         | Daratumumab (with hyaluronidase)                   | Monoclonal antibody     | Biosimilar <sup>(3)</sup>          | Subcutaneous injection | CD38 inhibitor with hyaluronidase                       | Multiple myeloma       | <div><div></div></div>     |                        |                         |                           |                        |     |                   | File IND application (2026)            | NMPA                | Self-developed | Mar 22, 2026                                               |
| Hematology                                     |                                                    |                         |                                    |                        |                                                         |                        |                            |                        |                         |                           |                        |     |                   |                                        |                     |                |                                                            |
| JY56                                           | Emicizumab                                         | Bispecific antibody     | Biosimilar <sup>(3)</sup>          | Subcutaneous injection | Bridging coagulation factor IX and coagulation factor X | Hemophilia             | <div><div></div></div>     |                        |                         |                           |                        |     |                   | File IND application (2026)            | NMPA                | Self-developed | Nov 17, 2031                                               |

### Notes:

- (1) As of the date of this report, we expected to conduct all the clinical trials of our product candidates in China and hold the exclusive rights to develop and commercialize such drug candidates worldwide.
- (2) After communicating with the CDE, it has agreed that we can directly enter the Phase III clinical trial on JY29-2 (Jikeqin) as we have completed the Phase I clinical trial of JY29-2 (Jiyoutai). We have completed the enrollment for the Phase III clinical trial of JY29-2 (jikeqin) on December 19, 2024.
- (3) We plan to collaborate with global pharmaceutical companies in the future to develop JY29-2 for markets outside of China where our partners will be responsible for clinical trials overseas.
- (4) According to the "Technical Guidelines for the Development and Evaluation of Biosimilars (Trial)" (《生物類似藥研發與評價技術指導原則(試行)》) issued by the CDE in 2015, biosimilars are only required to undergo Phase I and Phase III clinical trials.
- (5) The data are sourced from the China's Patent Information Registration Platform for Marketed Drugs, and the dates indicate the expiration of composition-of-matter (compound) patents for originator drugs.

# Management Discussion and Analysis

## Metabolic Disease Products

- The biosimilar JY29-2 (semaglutide injection) for the diabetes indication has completed the supplementary studies required for marketing application, and the clinical, statistical, and compliance reviews have been completed. For the weight loss indication, patient enrollment was completed in December 2024, and during the Reporting Period, the Company continued the study in accordance with the clinical protocol.
- We have newly initiated the project of a long-acting amylin analogue JY54-2 that is stable under neutral pH conditions, which has completed the confirmation of candidate molecules and is currently at the CMC research stage. Both JY54 and JY54-2 have demonstrated excellent pharmacological activity and safety in cell and animal models. The Company has established cooperation with professional consulting firms and is actively promoting the global business development and subsequent clinical development of these innovative molecules.
- For the Class I innovative drug JY47 (SIRP $\alpha$  monoclonal antibody injection), preclinical studies by the Company have indicated its potential for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and it is planned to apply for clinical trials of this new indication.
- In March 2025, the Company delivered a special presentation titled “Development of Antidiabetic and Anti-Obesity Drugs Targeting GLP-1” at the 10th Bio China 2025 EBC Biotech Industry Conference, introducing the Company’s phased achievements in the development of GLP-1-targeted drugs.
- In July 2025, at the 12th Biocon China Expo 2025 International Biopharmaceutical Lifecycle Technology Conference, the Company gave an oral report titled “Development of Next-Generation Long-Acting Amylin Analogue Peptide Drugs for Weight Loss and Diabetes”, sharing innovative strategies and project progress in the combination of GLP-1 and amylin drugs.
- As of the end of the Reporting Period, regarding the channel development for the semaglutide biosimilar, the Company had commenced recruitment and training of the commercialization team, as well as organization and planning of early-stage market education and academic activities.



# Management Discussion and Analysis

## Orthopedic Products

- JY23 (multipotent biological bone containing rhBMP-2) has successfully passed the registration inspection, and the interim report of the biological experiments has been obtained. The existing preclinical data, including biological and animal experimental data, indicate that JY23 is safe and effective; multiple pilot-scale production batches have been carried out, and all products have passed comprehensive inspection, indicating stable production processes and controllable quality. JY23 is planned to submit a marketing application in the first half of 2026.
- The Phase IV clinical trial for Guyoudao® (Registration No.: ChiCTR2300072199) – a prospective, multicenter, randomized, controlled clinical study of recombinant human bone morphogenetic protein-2 bone repair material (Guyoudao®) combined with cannulated compression screws in the treatment of femoral neck fractures in young and middle-aged adults – has been officially launched, and the patient enrollment is currently progressing in an orderly manner.
- We actively participate in the national key R&D program project “Research on Clinical Application Solutions for Oblique Lateral Interbody Fusion (OLIF) Based on Highly Osteoinductive Materials” (Project No.: 2022YFC2407200), and continue to deepen the exploration of the clinical application value of the products.

## Hematology and Oncology Products

- PEGylation human granulocyte colony-stimulating factor injection factor injection (brand name: Jixinfen®) was approved for marketing in January 2025. It is indicated for reducing the incidence of infections manifested as febrile neutropenia in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs that are likely to cause febrile neutropenia. As of the end of the Reporting Period, the new long-acting leukocyte-raising drug Jixinfen had completed market access listing in one-third of provinces nationwide.
- Avatrombopag maleate tablets (brand name: Jilixin®) were approved for marketing in June 2025. Approved indications: (1) For adult patients with chronic liver disease-associated thrombocytopenia who are scheduled to undergo diagnostic procedures or surgery; (2) For adult patients with chronic primary immune thrombocytopenia (ITP) who have had an insufficient response to previous treatments such as corticosteroids or immunoglobulins, to increase platelet counts and reduce or prevent bleeding. As of the end of the Reporting Period, the Company had initiated preliminary market access work for Jilixin®.

# Management Discussion and Analysis

## Intellectual Property

As of the end of the Reporting Period, the Company made new progress in intellectual property layout, with three new invention patent applications and one PCT international patent application:

- For the Class I innovative drug JY54 (long-acting amylin analogue): two new invention patent applications were filed, covering the core compound molecular structure and its application in the treatment of metabolic diseases.
- For JY23 (multipotent biological bone containing rhBMP-2): one new domestic invention patent application was filed, mainly protecting the composition formula and preparation process, and one PCT international patent application was submitted, covering the composition formula, preparation method, and therapeutic use.

## Internationalization Progress

In the first half of 2025, the Company actively advanced overseas business in line with the internationalization strategy for core products.

- In February, we entered into an exclusive distribution agreement for Guyoudao® with a customer in Indonesia, and the on-site audit has been completed.
- In March, the Company's Guyoudao product and quality management system passed the on-site inspection by Brazil's official authority ANVISA with zero defects.
- In May, the Company signed a commercialization agreement with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., we formed an important strategic alliance regarding exclusive clinical development, registration, production, and commercialization rights for products such as semaglutide, Guyoudao, and JY-23 in all countries of the Middle East and North Africa, Sub-Saharan Africa, and some ASEAN countries, further consolidating the Company's leading position in the region and expanding into the global innovative pharmaceutical market.
- Regarding the exclusive licensing of semaglutide with Kexing Biopharm Co., Ltd. in major Latin American countries, the relevant registration documents have been finalized, and it is expected that the marketing application and GMP certification application will be officially submitted to the Brazilian authorities within the year.
- The collaboration with Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. on PEGylation human granulocyte colony-stimulating factor is currently in active progress.



# Management Discussion and Analysis

## Talent Development and Compliance Culture

As of June 30, 2025, the Company had 1,629 employees. Talent development is the core driving force for the Company's high-quality growth. By integrating strategic planning, team building, capability reshaping, and technology integration, the Company has established a systematic training system. The Company has established and improved the existing job grade system and further optimized the compensation system to balance incentives and fairness. At the same time, we attach great importance to the working environment for employees, continuously provide a wide range of employee benefits, and organize various types of employee activities to enrich their work experience. We believe that building a talent pipeline is an important guarantee for advancing innovative products from R&D to commercialization.

Integrity, focus, co-creation, and progress are the Company's core values. We have always adhered to the business philosophy of honesty, trustworthiness, integrity, and compliance, with a focus on pharmaceuticals and strategic priorities. We are committed to building a high-level compliance system, strictly abiding by relevant national laws, regulations, and pharmaceutical industry regulatory policies, and contributing to human health with a gene engineering orientation.

## Future and Outlook

Guided by genetic engineering technology, we are committed developing into a leading biopharmaceutical company. After more than thirty years of development, the Company has successfully developed multiple first-in-China commercialized products. It has strong R&D capabilities in fields such as orthopedics and metabolism, and has laid out R&D pipelines with significant market potential.

During the Reporting Period, the government introduced a series of reform policies for the pharmaceutical industry, including optimizing collective procurement schemes, providing full-chain support for innovative drugs and the development of innovative medical devices. Policy support is helping the pharmaceutical industry achieve high-quality development through innovation and standardization. Leveraging these favorable industry policies and our efficient R&D system, we will continue to develop drug candidates in fields such as orthopedics, metabolism, oncology, and hematology and accelerate the R&D and marketing application processes for late-stage pipelines, providing continuous growth momentum for the Company's development. On the basis of independent R&D, we will also consider strengthening external cooperation and expanding our product pipeline through licensing, joint ventures, and other models, thus promoting the Company's innovation-driven transformation. In terms of capacity building, we will further enhance the production capacity for orthopedic products, macromolecule and peptide drugs, and further reduce costs by enhancing production capacity. In commercialization, we will continue to improve the construction of our marketing network and commercialization team, while cooperating with leading global pharmaceutical companies to expand our international commercial presence.

# Management Discussion and Analysis

## FINANCIAL REVIEW

### Revenue

During the Reporting Period, our revenue was RMB638.8 million, representing a decrease of 9.1% as compared to RMB702.4 million for the same period of 2024. The decrease in revenue was mainly attributable to a decrease of RMB23.4 million in revenue from sales of goods and a decrease of RMB40.2 million in revenue from pharmaceutical services.

### Sale of Goods

Revenue from sales of goods decreased by 3.6% from RMB645.2 million in the six months ended June 30, 2024 to RMB621.8 million in the six months ended June 30, 2025, primarily due to the decrease in revenue from Guyoudao. Our revenue generated from sales of Guyoudao decreased by 3.0% from RMB414.1 million in the six months ended June 30, 2024 to RMB401.7 million in the six months ended June 30, 2025, mainly due to a decrease in the average selling price of Guyoudao.

### Pharmaceutical Services

Revenue from pharmaceutical services decreased by 70.3% from RMB57.2 million in the six months ended June 30, 2024 to RMB17.0 million in the six months ended June 30, 2025, primarily because a smaller portion of commissioned manufacturing was scheduled for the first half of the year, with the majority concentrated in the second half, according to the annual commissioned manufacturing plan.

### Cost of Sales

Our cost of sales decreased by 29.8% from RMB161.8 million in the six months ended June 30, 2024 to RMB113.6 million in the six months ended June 30, 2025, primarily due to (i) a smaller proportion of commissioned manufacturing was scheduled in the first half of the year, with most of commissioned manufacturing activities concentrated in the second half, which resulted in lower pharmaceutical services revenue and a corresponding reduction in related costs; and (ii) a decrease in raw material costs for certain products compared with the same period of the prior year.

### Gross Profit and Gross Profit Margin

As a result of the foregoing, our gross profit decreased by 2.8% from RMB540.6 million in the six months ended June 30, 2024 to RMB525.2 million in the six months ended June 30, 2025. Our gross profit margin increased from 77.0% in the six months ended June 30, 2024 to 82.2% in the six months ended June 30, 2025, primarily attributable to (i) lower raw material costs, (ii) increased sales volume of higher-margin products, and (iii) a reduced contribution from lower-margin pharmaceutical services.

### Other Income and Gains

Our other income and gains increased from RMB9.2 million in the six months ended June 30, 2024 to RMB15.8 million in the six months ended June 30, 2025, primarily due to an increase in bank interest income.



# Management Discussion and Analysis

## Selling and Marketing Expenses

Our selling and marketing expenses remained stable at RMB341.5 million for the six months ended June 30, 2024 and RMB345.4 million for the six months ended June 30, 2025.

## Administrative Expenses

Our administrative expenses decreased from RMB33.8 million in the six months ended June 30, 2024 to RMB30.2 million in the six months ended June 30, 2025, primarily due to a decrease in listing expense.

## Research and Development Costs

Our research and development costs increased from RMB37.3 million in the six months ended June 30, 2024 to RMB49.6 million in the six months ended June 30, 2025, primarily due to increased investments as our R&D projects progressed.

## Other Expenses

Our other expenses increased from RMB3.5 million in the six months ended June 30, 2024 to RMB8.9 million in the six months ended June 30, 2025, primarily due to an increase in credit impairment losses.

## Finance Costs

Our finance costs decreased from RMB3.8 million in the six months ended June 30, 2024 to RMB2.7 million in the six months ended June 30, 2025, primarily due to a decrease in bank loan interest rates.


## Income Tax Expense

Our income tax expense decreased from RMB24.5 million in the six months ended June 30, 2024 to RMB14.1 million in the six months ended June 30, 2025, primarily due to a decrease in profit before tax and an increase in the amount of additional tax deductions for R&D expenses.

## Liquidity and Capital Resources

The Group maintained a sound financial position. As at June 30, 2025, we had cash and cash equivalents of RMB217.6 million (as at December 31, 2024: RMB537.6 million), time deposits with original maturity over three months of RMB300.2 million (as of December 31, 2024: nil). As at June 30, 2025, the Group had a balance of interest-bearing bank borrowings of RMB137.1 million (as at December 31, 2024: RMB119.8 million). As at June 30, 2025, the gearing ratio of the Group (total liabilities divided by total assets) was 21.7% (as at December 31, 2024: 21.1%).

Currently, the Group follows a set of funding and treasury policies to manage its capital resources and prevent risks involved. The Group expects to fund its working capital and other capital requirements from a combination of various sources, including but not limited to internal financing and external financing at reasonable market rates. In order to better control and decrease the cost of funds, the Group's treasury activities are centralized and all cash transactions are dealt with the banks with good reputation.



# Management Discussion and Analysis

Most assets and liabilities of the Group were denominated in RMB, HKD and Euro. Currently, the Group does not employ any financial instruments or enter into any foreign exchange contracts to hedge against foreign exchange risk. However, by closely monitoring the net exposure of foreign exchange risk, the Group managed the foreign exchange risk, thus minimizing the impact of foreign exchange fluctuations.

## Significant Investments, Material Acquisition and Disposal

The Group did not have any significant investments or material acquisitions or disposals of subsidiaries, associates and joint ventures for the six months ended June 30, 2025.

As of June 30, 2025, the Group did not have any significant investments.

## Future Plans for Material Investments or Capital Assets

As of the date of this report, the Group did not have any concrete future plans for material capital expenditure, investments or capital assets. We will make further announcement(s) in accordance with the Listing Rules, where applicable, if any investments and acquisition opportunities materialize.

## Charges on Group Assets

As of June 30, 2025, certain of our bank borrowings were secured by our buildings and leasehold land with carrying amounts of RMB146.1 million and nil, respectively.

## Employee Remuneration and Relations

As of June 30, 2025, the Group had a total of 1,629 full-time employees. We are committed to making sure that working conditions throughout our business network are safe and that employees are treated with care and respect. We believe we offer our employees competitive compensation and benefits packages, reflecting our stakeholder-centric ethos which we believe leads to sustainable and durable growth. As required by PRC regulations, we participate in various government statutory employee benefit plans, including social insurances, namely pension insurance, medical insurance, unemployment insurance, work-related injury insurance, maternity insurance, and housing funds. We are required under PRC law to make contributions to employee benefit plans at specified percentages of the salaries, bonuses and certain allowances of our employees, up to a maximum amount specified by the local government regulations from time to time. Our compensation package also comprises year-end bonuses, communication, transport and meal allowances, staff dormitory, paid leaves, and holiday benefits. In addition, we provide career development opportunities and promote an inventive, collaborative, and productive work environment, which we believe fosters long-lasting self-motivation for our employees.

Our employees typically enter into standard employment contracts with us. We place a high value on recruiting, training, and retaining qualified employees. We maintain high standards on selecting and recruiting talent worldwide and provide competitive compensation packages. Remuneration packages for our employees mainly comprise base salary and performance-based bonus. To maintain and enhance the quality, knowledge and skill levels of our workforce as well as their familiarity with industry quality standards and work safety standards, we provide our employees with periodic training, including orientation programs for new employees, technical training, professional and management training and health and safety training.

## Contingent Liabilities

The Group did not have any material contingent liabilities as at June 30, 2025.

## Corporate Governance and Other Information

### DIRECTORS', SUPERVISORS' AND CHIEF EXECUTIVE'S INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES OF THE COMPANY OR ITS ASSOCIATED CORPORATIONS

Save as disclosed below, as at June 30, 2025, no other Directors, Supervisors and chief executive of the Company had any interests and/or short positions in the Shares, underlying Shares and debentures of the Company and any interests and/or short positions in shares, underlying shares or debentures of any of the Company's associated corporations (within the meaning of Part XV of the SFO) which (i) were required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and/or short positions which they are taken or deemed to have under such provisions of the SFO), (ii) were required, pursuant to Section 352 of the SFO, to be entered in the register referred to therein or (iii) were required, pursuant to the Model Code, to be notified to the Company and the Stock Exchange:

| Name of Director,<br>Supervisor or<br>Chief Executive of<br>the Company | Nature of Interest                     | Description<br>of the Shares | Number of<br>Shares Held or<br>Interested | Approximate<br>percentage of<br>shareholding<br>in the<br>relevant<br>class of<br>Shares <sup>(1)</sup> | Approximate<br>percentage of<br>shareholding<br>in the total<br>share<br>capital of<br>our<br>Company <sup>(1)</sup> |
|-------------------------------------------------------------------------|----------------------------------------|------------------------------|-------------------------------------------|---------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------|
| Mr. Fu Hang <sup>(2)</sup>                                              | Interest in controlled<br>corporations | Unlisted Shares              | 3,285,425                                 | 2.41%                                                                                                   | 1.34%                                                                                                                |
|                                                                         |                                        | H Shares                     | 1,760,073                                 | 1.61%                                                                                                   | 0.72%                                                                                                                |

Notes:

- (1) The calculation is based on the total number of 136,302,015 Unlisted Shares and 109,096,785 H Shares in issue as at June 30, 2025. All interests stated are long positions.
- (2) As at June 30, 2025, Mr. Fu Hang was the general partner who held 34.68% partnership interests in Nanbeiju. As such, Mr. Fu Hang was deemed to be interested in the 1,760,073 H Shares and 3,285,425 Unlisted Shares directly held by Nanbeiju under the SFO.

## Corporate Governance and Other Information

### SUBSTANTIAL SHAREHOLDERS' INTERESTS AND SHORT POSITIONS IN THE SHARES AND UNDERLYING SHARES OF THE COMPANY

So far as the Directors are aware, as at June 30, 2025, the following persons (other than the Directors, Supervisors or chief executive of the Company as disclosed above) had interests and/or short positions in the Shares or the underlying Shares which would fall to be disclosed to the Company and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO, and which would be recorded in the register required to be kept under Section 336 of the SFO, or, who are, directly or indirectly interested in 5% or more of the nominal value of any class of the share capital carrying rights to vote in all circumstances at general meetings of the Company:

| Name of Shareholder                                                     | Nature of Interest                                  | Description of the Shares | Number of Shares Held or Interested | Approximate percentage of interest in the Unlisted Shares/ H Shares (as appropriate <sup>(1)</sup> ) (%) | Approximate percentage of interest in the Company <sup>(1)</sup> (%) |
|-------------------------------------------------------------------------|-----------------------------------------------------|---------------------------|-------------------------------------|----------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------|
| Zhongmei Huadong                                                        | Beneficial owner                                    | Unlisted Shares           | 29,484,317                          | 21.63                                                                                                    | 12.01                                                                |
|                                                                         |                                                     | H Shares                  | 12,636,136                          | 11.58                                                                                                    | 5.15                                                                 |
| Huadong Medicine                                                        | Interest in a controlled corporation <sup>(2)</sup> | Unlisted Shares           | 29,484,317                          | 21.63                                                                                                    | 12.01                                                                |
|                                                                         |                                                     | H Shares                  | 12,636,136                          | 11.58                                                                                                    | 5.15                                                                 |
| China Grand Enterprises, Inc.<br>(中國遠大集團有限責任公司)                         | Interest in a controlled corporation <sup>(2)</sup> | Unlisted Shares           | 29,484,317                          | 21.63                                                                                                    | 12.01                                                                |
|                                                                         |                                                     | H Shares                  | 12,636,136                          | 11.58                                                                                                    | 5.15                                                                 |
| Beijing Yuanda Huachuang Investment Group Co., Ltd.<br>(北京遠大華創投資集團有限公司) | Interest in a controlled corporation <sup>(2)</sup> | Unlisted Shares           | 29,484,317                          | 21.63                                                                                                    | 12.01                                                                |
|                                                                         |                                                     | H Shares                  | 12,636,136                          | 11.58                                                                                                    | 5.15                                                                 |
| Hu Kaijun (胡凱軍)                                                         | Interest in a controlled corporation <sup>(2)</sup> | Unlisted Shares           | 29,484,317                          | 21.63                                                                                                    | 12.01                                                                |
|                                                                         |                                                     | H Shares                  | 12,636,136                          | 11.58                                                                                                    | 5.15                                                                 |
| Hangzhou Huasheng                                                       | Beneficial owner                                    | Unlisted Shares           | 25,998,521                          | 19.07                                                                                                    | 10.59                                                                |
|                                                                         |                                                     | H Shares                  | 6,499,630                           | 5.96                                                                                                     | 2.65                                                                 |
| Hangzhou Wanyuhe Pharmaceutical Technology Co., Ltd.<br>(杭州萬裕和醫藥科技有限公司) | Interest in a controlled corporation <sup>(3)</sup> | Unlisted Shares           | 25,998,521                          | 19.07                                                                                                    | 10.59                                                                |
|                                                                         |                                                     | H Shares                  | 6,499,630                           | 5.96                                                                                                     | 2.65                                                                 |

## Corporate Governance and Other Information

| Name of Shareholder                                                                                                   | Nature of Interest                                                    | Description of the Shares | Number of Shares Held or Interested | Approximate percentage of interest in the Unlisted Shares/ H Shares (as appropriate <sup>(1)</sup> ) (%) | Approximate percentage of interest in the Company <sup>(1)</sup> (%) |
|-----------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------|---------------------------|-------------------------------------|----------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------|
| Li Bangliang (李邦良)                                                                                                    | Beneficial owner, Interest in a controlled corporation <sup>(3)</sup> | Unlisted Shares           | 28,331,705                          | 20.79                                                                                                    | 11.55                                                                |
|                                                                                                                       |                                                                       | H Shares                  | 6,499,630                           | 5.96                                                                                                     | 2.65                                                                 |
| CQFE                                                                                                                  | Beneficial owner                                                      | Unlisted Shares           | 24,000,000                          | 17.61                                                                                                    | 9.78                                                                 |
|                                                                                                                       |                                                                       | H Shares                  | 6,000,000                           | 5.50                                                                                                     | 2.44                                                                 |
| Heda HK                                                                                                               | Beneficial owner                                                      | Unlisted Shares           | Nil                                 | –                                                                                                        | –                                                                    |
|                                                                                                                       |                                                                       | H Shares                  | 12,400,400                          | 11.37                                                                                                    | 5.05                                                                 |
| Hangzhou Heda Jinyuan Equity Investment Fund Partnership Enterprise (Limited Partnership)<br>(杭州和達金源股權投資基金合夥企業(有限合夥)) | Interest in a controlled corporation <sup>(4)</sup>                   | Unlisted Shares           | Nil                                 | –                                                                                                        | –                                                                    |
|                                                                                                                       |                                                                       | H Shares                  | 12,400,400                          | 11.37                                                                                                    | 5.05                                                                 |
| Hangzhou Heda Industry Fund Investment Co., Ltd.<br>(杭州和達產業基金投資有限公司)                                                  | Interest in a controlled corporation <sup>(4)</sup>                   | Unlisted Shares           | Nil                                 | –                                                                                                        | –                                                                    |
|                                                                                                                       |                                                                       | H Shares                  | 12,400,400                          | 11.37                                                                                                    | 5.05                                                                 |
| Hangzhou Hegang Venture Capital Co., Ltd.<br>(杭州和港創業投資有限公司)                                                           | Interest in a controlled corporation <sup>(4)</sup>                   | Unlisted Shares           | Nil                                 | –                                                                                                        | –                                                                    |
|                                                                                                                       |                                                                       | H Shares                  | 12,400,400                          | 11.37                                                                                                    | 5.05                                                                 |
| Hangzhou Heda Investment Management Co., Ltd.<br>(杭州和達投資管理有限公司)                                                       | Interest in a controlled corporation <sup>(4)</sup>                   | Unlisted Shares           | Nil                                 | –                                                                                                        | –                                                                    |
|                                                                                                                       |                                                                       | H Shares                  | 12,400,400                          | 11.37                                                                                                    | 5.05                                                                 |
| Hangzhou Heda Financial Services Group Co., Ltd.<br>(杭州和達金融服務集團有限公司)                                                  | Interest in a controlled corporation <sup>(4)</sup>                   | Unlisted Shares           | Nil                                 | –                                                                                                        | –                                                                    |
|                                                                                                                       |                                                                       | H Shares                  | 12,400,400                          | 11.37                                                                                                    | 5.05                                                                 |

## Corporate Governance and Other Information

| Name of Shareholder                                                                     | Nature of Interest                                  | Description of the Shares   | Number of Shares Held or Interested | Approximate percentage of interest in the Unlisted Shares/ H Shares (as appropriate <sup>(1)</sup> ) (%) | Approximate percentage of interest in the Company <sup>(1)</sup> (%) |
|-----------------------------------------------------------------------------------------|-----------------------------------------------------|-----------------------------|-------------------------------------|----------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------|
| Hangzhou Qiantang New Area Industrial Development Group Co., Ltd.<br>(杭州錢塘新區產業發展集團有限公司) | Interest in a controlled corporation <sup>(4)</sup> | Unlisted Shares<br>H Shares | Nil<br>12,400,400                   | –<br>11.37                                                                                               | –<br>5.05                                                            |
| Hangzhou Qiantang New Area Management Committee<br>(杭州錢塘新區管理委員會)                        | Interest in a controlled corporation                | Unlisted Shares<br>H Shares | Nil<br>12,400,400                   | –<br>11.37                                                                                               | –<br>5.05                                                            |
| Zhejiang Wangxin                                                                        | Beneficial owner                                    | Unlisted Shares<br>H Shares | 12,256,887<br>12,256,888            | 8.99<br>11.23                                                                                            | 4.99<br>4.99                                                         |
| Inigma Technology Co., Ltd.<br>(浙大網新科技股份有限公司)                                           | Interest in a controlled corporation <sup>(5)</sup> | Unlisted Shares<br>H Shares | 12,256,887<br>12,256,888            | 8.99<br>11.23                                                                                            | 4.99<br>4.99                                                         |
| Highland Pharma                                                                         | Beneficial owner                                    | Unlisted Shares<br>H Shares | 7,000,000<br>13,000,000             | 5.14<br>11.92                                                                                            | 2.85<br>5.30                                                         |
| Nice Bonus Limited (增好有限公司)                                                             | Interest in a controlled corporation <sup>(6)</sup> | Unlisted Shares<br>H Shares | 7,000,000<br>13,000,000             | 5.14<br>11.92                                                                                            | 2.85<br>5.30                                                         |
| Yang Loon Chun (楊麟振)                                                                    | Interest in a controlled corporation <sup>(6)</sup> | Unlisted Shares<br>H Shares | 7,000,000<br>13,000,000             | 5.14<br>11.92                                                                                            | 2.85<br>5.30                                                         |
| Hangzhou Investment                                                                     | Beneficial owner                                    | Unlisted Shares<br>H Shares | 17,429,338<br>Nil                   | 12.79<br>–                                                                                               | 7.10<br>–                                                            |

### Notes:

- (1) The calculation is based on the total number of 136,302,015 Unlisted Shares and 109,096,785 H Shares in issue as at June 30, 2025. All interests stated are long positions.
- (2) As at June 30, 2025, Zhongmei Huadong was wholly owned by Huadong Medicine. Huadong Medicine was owned as to 41.67% by China Grand Enterprises, Inc. (中國遠大集團有限責任公司). China Grand Enterprises, Inc. was in turn owned as to 92.97% by Beijing Yuanda Huachuang Investment Group Co., Ltd. (北京遠大華創投資集團有限公司), a wholly owned company of Mr. Hu Kaijun (胡凱軍). As such, each of Huadong Medicine, China Grand Enterprises, Inc., Beijing Yuanda Huachuang Investment Group Co., Ltd. and Hu Kaijun was deemed to be interested in the 42,120,453 Shares directly held by Zhongmei Huadong under the SFO.



## Corporate Governance and Other Information

- (3) As at June 30, 2025, Hangzhou Huasheng was owned as to 39.57% by Hangzhou Wanyuhe Pharmaceutical Technology Co., Ltd. (杭州萬裕和醫藥科技有限公司), which is owned as to 99% by Mr. Li Bangliang (李邦良). As such, each of Hangzhou Wanyuhe Pharmaceutical Technology Co., Ltd. and Mr. Li Bangliang was deemed to be interested in the 32,498,151 Shares directly held by Hangzhou Huasheng under the SFO.
- (4) As at June 30, 2025, Heda HK was wholly owned by Hangzhou Heda Jinyuan Equity Investment Fund Partnership Enterprise (Limited Partnership) (杭州和達金源股權投資基金合夥企業 (有限合夥)) (“Hangzhou Heda”), a limited liability partnership established under the laws of the PRC. As of the date of this interim report, Hangzhou Heda was held as to (i) 99.95% by Hangzhou Heda Industry Fund Investment Co., Ltd. (杭州和達產業基金投資有限公司) (“Heda Industry Fund”) as its limited partner, and (ii) 0.05% by Hangzhou Heda Investment Management Co., Ltd. (杭州和達投資管理有限公司) (“Heda Investment Management”) as its general and executive partner, respectively. Heda Industry Fund was wholly owned by Hangzhou Hegang Venture Capital Co., Ltd. (杭州和港創業投資有限公司), which was in turn wholly owned by Hangzhou Qiantang New Area Industrial Development Group Co., Ltd. (杭州錢塘新區產業發展集團有限公司) (“Qiantang New Area Industrial”). Heda Investment Management was owned as to 90% by Hangzhou Heda Financial Services Group Co., Ltd. (杭州和達金融服務集團有限公司), which was in turn wholly owned by Qiantang New Area Industrial. Qiantang New Area Industrial was owned as to 90% directly by Hangzhou Qiantang New Area Management Committee (杭州錢塘新區管理委員會). As such, each of Hangzhou Heda, Heda Industry Fund, Heda Investment Management, Hangzhou Hegang Venture Capital Co., Ltd., Qiantang New Area Industrial, Hangzhou Heda Financial Services Group Co., Ltd. and Hangzhou Qiantang New Area Management Committee was deemed to be interested in the 12,400,400 Shares directly held by Heda HK under the SFO.
- (5) As at June 30, 2025, Zhejiang Wangxin was wholly owned by Insigma Technology Co., Ltd. (浙大網新科技股份有限公司). As such, Insigma Technology Co., Ltd. was deemed to be interested in the 24,513,775 Shares directly held by Zhejiang Wangxin under the SFO.
- (6) As at June 30, 2025, Highland Pharma was wholly owned by Nice Bonus Limited (增好有限公司). Nice Bonus Limited was owned as to 99.00% by Yang Loon Chun (楊麟振). As such, each of Nice Bonus Limited and Yang Loon Chun was deemed to be interested in the 20,000,000 Shares directly held by Highland Pharma under the SFO.

Save as disclosed above, the Directors are not aware of any person who had an interest and/or short position in the Shares or the underlying Shares which would fall to be disclosed to the Company and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO, and which would be recorded in the register required to be kept under Section 336 of the SFO, or, who are, directly or indirectly interested in 5% or more of the nominal value of any class of the share capital carrying rights to vote in all circumstances at general meetings of the Company or any other member of the Group.

### DIRECTORS’ AND SUPERVISORS’ RIGHTS TO ACQUIRE SHARES OR DEBENTURES

No arrangement has been made by the Company, its holding company, or any of its subsidiaries for any Director or Supervisor to acquire benefits by means of the acquisition of shares in, or debt securities (including debentures) of, the Company or any other corporate body during the Reporting Period, and none of the Directors, Supervisors, their spouses, or their children under the age of 18 have the right to subscribe for the share capital or debt securities of the Company or any other legal entity, nor have they exercised such rights.

### USE OF PROCEEDS FROM THE GLOBAL OFFERING

The net proceeds from the global offering by the Company (after deducting the underwriting fees and related Listing expenses) amounted to approximately HK\$478.66 million (equivalent to RMB442.28 million) (1), and the balance of unutilized net proceeds is approximately RMB392.69 million as at June 30, 2025.

## Corporate Governance and Other Information

The net proceeds have been and will be utilized in accordance with the purposes set out in the Prospectus. The table below sets out the planned applications of the net proceeds and actual usage as of June 30, 2025. Any discrepancies in this table between the total and sums of amounts are due to rounding.

| Use of Proceeds                                                                                                                                                                                                                               |        | Allocation of<br>Net Proceeds<br>(HK\$ in million) | Allocation of<br>Net Proceeds<br>(RMB in million) | Unutilized<br>Amount<br>(as of<br>December<br>31, 2024)<br>(RMB in million) | Utilized<br>Amount<br>during the<br>Reporting<br>Period | Unutilized<br>Amount<br>(as of<br>June<br>30, 2025)<br>(RMB in million) | Expected<br>Timeline for<br>Full Utilization<br>of the Unutilized<br>Net Proceeds |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|----------------------------------------------------|---------------------------------------------------|-----------------------------------------------------------------------------|---------------------------------------------------------|-------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| <b>For continued research and development of our selected product candidates in our strategically focused therapeutic areas</b>                                                                                                               | 40.2%  | 192.57                                             | 177.93                                            | 177.93                                                                      | 12.79                                                   | 165.14                                                                  | December 2027                                                                     |
| For continued research and development of our selected metabolic disease product candidates that are currently at preclinical stage, pending the initiation of clinical trials, or pending NDA                                                | 20.9%  | 99.80                                              | 92.22                                             | 92.22                                                                       | 10.38                                                   | 81.84                                                                   | December 2027                                                                     |
| For continued research and development of our selected orthopedic product candidates that are currently at preclinical stage                                                                                                                  | 9.1%   | 43.56                                              | 40.25                                             | 40.25                                                                       | 1.54                                                    | 38.71                                                                   | December 2027                                                                     |
| For continued research and development of our selected oncology product candidates that are currently at preclinical stage or pending the initiation of clinical trials                                                                       | 10.3%  | 49.16                                              | 45.42                                             | 45.42                                                                       | 0.87                                                    | 44.55                                                                   | December 2027                                                                     |
| <b>For marketing and commercialization of our existing and near-commercialized products</b>                                                                                                                                                   | 29.9%  | 143.07                                             | 132.20                                            | 132.20                                                                      | 5.88                                                    | 126.32                                                                  | December 2027                                                                     |
| For expansion of our sales and marketing team                                                                                                                                                                                                 | 24.9%  | 119.23                                             | 110.17                                            | 110.17                                                                      | 4.42                                                    | 105.75                                                                  | December 2027                                                                     |
| For intensifying market publicity and development of our marketed product                                                                                                                                                                     | 5.0%   | 23.84                                              | 22.03                                             | 22.03                                                                       | 1.45                                                    | 20.57                                                                   | December 2027                                                                     |
| <b>For strategic collaboration to enrich our product portfolio in our targeted therapeutic areas</b>                                                                                                                                          | 10.0%  | 47.67                                              | 44.05                                             | 44.05                                                                       | –                                                       | 44.05                                                                   | December 2027                                                                     |
| <b>For our manufacturing system to construct new production lines, and to upgrade and further automate our existing production facilities to prepare for the potential increase in demand for our products and the launch of new products</b> | 10.0%  | 47.67                                              | 44.05                                             | 44.05                                                                       | 0.07                                                    | 43.98                                                                   | December 2027                                                                     |
| <b>For working capital and other general corporate purposes</b>                                                                                                                                                                               | 10.0%  | 47.67                                              | 44.05                                             | 44.05                                                                       | 30.86                                                   | 13.19                                                                   | December 2026                                                                     |
|                                                                                                                                                                                                                                               | 100.0% | 478.66                                             | 442.28                                            | 442.28                                                                      | 49.60                                                   | 392.69                                                                  |                                                                                   |

Note:

- (1) The net proceeds were received in HKD and translated to RMB at the rate of HKD1.00 to RMB0.924 quoted by the People's Bank of China for foreign exchange transactions prevailing on November 28, 2024 for illustration purpose.



## Corporate Governance and Other Information

### **PURCHASE, SALE OR REDEMPTION OF THE LISTED SECURITIES OF THE COMPANY**

During the Reporting Period, neither the Company nor its subsidiary has purchased, sold or redeemed any of the Company's listed securities (including the sale of treasury shares). As of June 30, 2025, there were no treasury shares held by the Company.

### **CONVERTIBLE BONDS**

During the Reporting Period, the Group did not issue any convertible bonds.

### **COMPLIANCE WITH THE CORPORATE GOVERNANCE CODE**

The Company has adopted the principles and code provisions as set out in the CG Code contained in Appendix C1 to the Listing Rules.

During the Reporting Period, the Company has complied with the code provisions in the CG Code, except for code provision C.2.1 as explained below.

Pursuant to code provision C.2.1 of Part 2 of the CG Code, companies listed on the Stock Exchange are expected to comply with but may choose to deviate from the requirement that the responsibilities between the chairman and the general manager should be segregated and should not be performed by the same individual. We do not have a separate chairman and general manager and Mr. Fu Hang currently performs these two roles. The Board believes that vesting the roles of both the chairman and general manager in the same person has the benefit of ensuring consistent leadership within the Group and enables more effective and efficient overall strategic planning for the Group. The Board considers that the balance of power and authority for the present arrangement will not be impaired and this structure will enable the Company to make and implement decisions promptly and effectively. In addition, all major decisions are made in consultation with members of the Board, including the relevant Board committees, and three independent non-executive Directors. The Board will continue to review and consider splitting the roles of the chairman of the Board and the general manager of the Company if and when it is appropriate taking into account the circumstances of the Group as a whole.

In order to maintain a high standard of corporate governance, the Board will continue to review and monitor the operation of the Company.

### **COMPLIANCE WITH THE MODEL CODE FOR SECURITIES TRANSACTIONS BY DIRECTORS AND SUPERVISORS**

The Company has adopted the Model Code to regulate all dealings by Directors, Supervisors and relevant employees who, because of such office or employment, are likely to possess inside information in relation to the Company or its securities. The Company has also devised its own code of conduct regarding Directors' dealings in the Company's securities (the "Code of Conduct") on terms no less exacting than the Model Code.

Specific enquiry has been made of all the Directors and Supervisors, and the Directors and Supervisors have confirmed that they have complied with the Code of Conduct during the Reporting Period. No incident of non-compliance of the Model Code by the relevant employees was noted by the Company during the Reporting Period.

# Corporate Governance and Other Information

## CHANGES IN INFORMATION OF DIRECTORS, SUPERVISORS AND CHIEF EXECUTIVE OF THE COMPANY

There were no material changes in the Directors', Supervisors' and chief executive's information required to be disclosed pursuant to Rule 13.51B(1) of the Listing Rules during the Reporting Period and as at the date of this interim report.

## REVIEW OF INTERIM RESULTS BY THE AUDIT COMMITTEE

The Company has established an Audit Committee with written terms of reference in compliance with Rule 3.21 of the Listing Rules and the CG Code. The Audit Committee comprises three independent non-executive Directors Mr. Zhou Zhihui, Ms. Ho Mei Yi and Dr. Zhou Demin, with Mr. Zhou Zhihui (being our independent non-executive Director with the appropriate professional qualifications) as chairman of the Audit Committee in compliance with Rules 3.10(2) and 3.21 of the Listing Rules.

The Audit Committee has considered and reviewed the unaudited interim financial information for the Reporting Period and the accounting principles and practices adopted by the Group and has discussed with the management on issues in relation to internal control, risk management and financial reporting.

## CONTINUING DISCLOSURE OBLIGATIONS PURSUANT TO THE LISTING RULES

As of June 30, 2025, the Company did not have any other disclosure obligations under Rules 13.20, 13.21 and 13.22 of the Listing Rules.

## INTERIM DIVIDENDS

The Board does not recommend the payment of an interim dividend to the Shareholders for the Reporting Period.

## EVENTS AFTER THE REPORTING PERIOD

Save as disclosed in this report and as at the date of this report, there were no material subsequent events after the Reporting Period.

By order of the Board

**Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.**

杭州九源基因生物醫藥股份有限公司

**Mr. Fu Hang**

*Chairman of the Board, Executive Director and General Manager*

Hangzhou, PRC

September 23, 2025

# Interim Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income

For the six months ended 30 June 2025

|                                                                                     | Notes | Six months ended 30 June       |                              |
|-------------------------------------------------------------------------------------|-------|--------------------------------|------------------------------|
|                                                                                     |       | 2025<br>RMB'000<br>(Unaudited) | 2024<br>RMB'000<br>(Audited) |
| <b>REVENUE</b>                                                                      | 4     | <b>638,778</b>                 | 702,360                      |
| Cost of sales                                                                       |       | (113,559)                      | (161,800)                    |
| Gross profit                                                                        |       | 525,219                        | 540,560                      |
| Other income and gains                                                              |       | 15,835                         | 9,163                        |
| Selling and marketing expenses                                                      |       | (345,364)                      | (341,549)                    |
| Administrative expenses                                                             |       | (30,183)                       | (33,759)                     |
| Research and development costs                                                      |       | (49,627)                       | (37,288)                     |
| Other expenses                                                                      |       | (8,928)                        | (3,505)                      |
| Finance costs                                                                       |       | (2,689)                        | (3,789)                      |
| <b>PROFIT BEFORE TAX</b>                                                            | 5     | <b>104,263</b>                 | 129,833                      |
| Income tax expense                                                                  | 6     | (14,089)                       | (24,485)                     |
| <b>PROFIT FOR THE PERIOD</b>                                                        |       | <b>90,174</b>                  | 105,348                      |
| <b>TOTAL COMPREHENSIVE INCOME FOR THE PERIOD</b>                                    |       | <b>90,174</b>                  | 105,348                      |
| Profit attributable to:<br>Owners of the parent                                     |       | 90,174                         | 105,348                      |
| Total comprehensive income attributable to:<br>Owners of the parent                 |       | 90,174                         | 105,348                      |
| <b>EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY<br/>EQUITY HOLDERS OF THE PARENT</b> |       |                                |                              |
| Basic and diluted (RMB)                                                             | 8     | 0.37                           | 0.53                         |

# Interim Condensed Consolidated Statement of Financial Position

30 June 2025

|                                                        | Notes | 30 June<br>2025<br>RMB'000<br>(Unaudited) | 31 December<br>2024<br>RMB'000<br>(Audited) |
|--------------------------------------------------------|-------|-------------------------------------------|---------------------------------------------|
| <b>NON-CURRENT ASSETS</b>                              |       |                                           |                                             |
| Property, plant and equipment                          | 9     | 339,823                                   | 352,977                                     |
| Right-of-use assets                                    |       | 52,372                                    | 1,254                                       |
| Intangible assets                                      |       | 190,520                                   | 157,816                                     |
| Prepayments, other receivables and other assets        |       | 5,754                                     | 1,001                                       |
| Total non-current assets                               |       | 588,469                                   | 513,048                                     |
| <b>CURRENT ASSETS</b>                                  |       |                                           |                                             |
| Inventories                                            |       | 151,122                                   | 149,123                                     |
| Trade and bills receivables                            | 10    | 720,335                                   | 672,178                                     |
| Prepayments, other receivables and other assets        |       | 24,114                                    | 13,650                                      |
| Due from related parties                               | 14    | 38,812                                    | 37,374                                      |
| Restricted bank deposits                               |       | 20                                        | 20                                          |
| Time deposits with original maturity over three months |       | 300,192                                   | –                                           |
| Cash and cash equivalents                              |       | 217,570                                   | 537,629                                     |
| Total current assets                                   |       | 1,452,165                                 | 1,409,974                                   |
| <b>CURRENT LIABILITIES</b>                             |       |                                           |                                             |
| Trade payables                                         | 11    | 35,382                                    | 27,000                                      |
| Lease liabilities                                      |       | 3,209                                     | 937                                         |
| Other payables and accruals                            |       | 172,805                                   | 196,098                                     |
| Due to related parties                                 | 14    | 1,032                                     | 644                                         |
| Interest-bearing bank borrowings                       |       | 91,872                                    | 81,014                                      |
| Contract liabilities                                   |       | 13,818                                    | 21,626                                      |
| Tax payable                                            |       | 4,639                                     | 14,366                                      |
| Total current liabilities                              |       | 322,757                                   | 341,685                                     |
| <b>NET CURRENT ASSETS</b>                              |       | 1,129,408                                 | 1,068,289                                   |
| <b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>           |       | 1,717,877                                 | 1,581,337                                   |

# Interim Condensed Consolidated Statement of Financial Position

30 June 2025

|                                             | Notes | 30 June<br>2025<br>RMB'000<br>(Unaudited) | 31 December<br>2024<br>RMB'000<br>(Audited) |
|---------------------------------------------|-------|-------------------------------------------|---------------------------------------------|
| <b>NON-CURRENT LIABILITIES</b>              |       |                                           |                                             |
| Lease liabilities                           |       | 48,789                                    | —                                           |
| Interest-bearing bank borrowings            |       | 45,192                                    | 38,769                                      |
| Other payables and accruals                 |       | 11,491                                    | 8,056                                       |
| Deferred tax liabilities                    |       | 15,139                                    | 16,501                                      |
| Total non-current liabilities               |       | 120,611                                   | 63,326                                      |
| <b>Net assets</b>                           |       | <b>1,597,266</b>                          | <b>1,518,011</b>                            |
| <b>EQUITY</b>                               |       |                                           |                                             |
| Equity attributable to owners of the parent |       |                                           |                                             |
| Share capital                               | 12    | 245,399                                   | 245,399                                     |
| Reserves                                    |       | 1,351,867                                 | 1,272,612                                   |
| <b>Total equity</b>                         |       | <b>1,597,266</b>                          | <b>1,518,011</b>                            |

# Interim Condensed Consolidated Statement of Changes in Equity

Six months ended 30 June 2025 (unaudited)

|                                                      | Attributable to owners of the parent |                           |                                 |                             |                              |                         |
|------------------------------------------------------|--------------------------------------|---------------------------|---------------------------------|-----------------------------|------------------------------|-------------------------|
|                                                      | Share capital<br>RMB'000             | Share premium*<br>RMB'000 | Share award reserve*<br>RMB'000 | Surplus reserve*<br>RMB'000 | Retained profits*<br>RMB'000 | Total equity<br>RMB'000 |
| At 1 January 2025 (audited)                          | 245,399                              | 1,112,250                 | 9,601                           | 15,076                      | 135,685                      | 1,518,011               |
| Profit and total comprehensive income for the period | –                                    | –                         | –                               | –                           | 90,174                       | 90,174                  |
| Dividend declared (note 7)                           | –                                    | –                         | –                               | –                           | (13,734)                     | (13,734)                |
| Equity-settled share award arrangements              | –                                    | –                         | 2,815                           | –                           | –                            | 2,815                   |
| At 30 June 2025 (unaudited)                          | 245,399                              | 1,112,250                 | 12,416                          | 15,076                      | 212,125                      | 1,597,266               |

Six months ended 30 June 2024 (audited)

|                                                      | Attributable to owners of the parent |                          |                                |                            |                             |                         |
|------------------------------------------------------|--------------------------------------|--------------------------|--------------------------------|----------------------------|-----------------------------|-------------------------|
|                                                      | Share capital<br>RMB'000             | Share premium<br>RMB'000 | Share award reserve<br>RMB'000 | Surplus reserve<br>RMB'000 | Retained profits<br>RMB'000 | Total equity<br>RMB'000 |
| At 1 January 2024 (audited)                          | 200,000                              | 681,430                  | 4,302                          | 1,216                      | 10,944                      | 897,892                 |
| Profit and total comprehensive income for the period | –                                    | –                        | –                              | –                          | 105,348                     | 105,348                 |
| Equity-settled share award arrangements              | –                                    | –                        | 3,036                          | –                          | –                           | 3,036                   |
| At 30 June 2024 (audited)                            | 200,000                              | 681,430                  | 7,338                          | 1,216                      | 116,292                     | 1,006,276               |

\* These reserve accounts comprise the consolidated reserves of RMB1,351,867,000 (unaudited) in the interim condensed consolidated statement of financial position as at 30 June 2025.

# Interim Condensed Consolidated Statement of Cash Flows

For the six months ended 30 June 2025

|                                                             |       | Six months ended 30 June       |                              |
|-------------------------------------------------------------|-------|--------------------------------|------------------------------|
|                                                             | Notes | 2025<br>RMB'000<br>(Unaudited) | 2024<br>RMB'000<br>(Audited) |
| <b>CASH FLOWS FROM OPERATING ACTIVITIES</b>                 |       |                                |                              |
| Profit before tax                                           |       | 104,263                        | 129,833                      |
| Adjustments for:                                            |       |                                |                              |
| Finance costs                                               |       | 2,689                          | 3,789                        |
| Interest income                                             |       | (7,757)                        | (138)                        |
| Loss on disposal of items of property, plant and equipment  | 5     | 8                              | 107                          |
| Equity-settled share award expense                          |       | 2,815                          | 3,036                        |
| Depreciation of property, plant and equipment               |       | 18,350                         | 17,481                       |
| Depreciation of right-of-use assets                         |       | 706                            | 418                          |
| Amortisation of intangible assets                           |       | 3,407                          | 294                          |
| Impairment losses on financial assets, net                  | 5     | 8,857                          | 2,999                        |
| Write-down of inventories to net realisable value           | 5     | 1,029                          | 6,310                        |
| Foreign exchange differences, net                           | 5     | (1,380)                        | –                            |
|                                                             |       | 132,987                        | 164,129                      |
| Increase/(decrease) in inventories                          |       | (3,028)                        | 5,493                        |
| Increase in trade and bills receivables                     |       | (50,488)                       | (79,638)                     |
| Increase in prepayments, other receivables and other assets |       | (11,999)                       | (7,575)                      |
| Increase in amounts due from related parties                |       | (7,739)                        | (50,263)                     |
| Increase/(decrease) in trade payables                       |       | 8,382                          | (10,857)                     |
| Decrease in other payables and accruals                     |       | (30,564)                       | (22,706)                     |
| Increase in amounts due to related parties                  |       | 388                            | 751                          |
| (Decrease)/increase in contract liabilities                 |       | (7,808)                        | 184                          |
| Cash generated from/(used in) operations                    |       | 30,131                         | (482)                        |
| Interest received                                           |       | 7,565                          | 138                          |
| Income tax paid                                             |       | (25,178)                       | (12,193)                     |
| Net cash flows from/(used in) operating activities          |       | 12,518                         | (12,537)                     |

# Interim Condensed Consolidated Statement of Cash Flows

For the six months ended 30 June 2025

|                                                                                                           | Six months ended 30 June |               |
|-----------------------------------------------------------------------------------------------------------|--------------------------|---------------|
|                                                                                                           | 2025                     | 2024          |
|                                                                                                           | RMB'000                  | RMB'000       |
|                                                                                                           | (Unaudited)              | (Audited)     |
| <b>CASH FLOWS FROM INVESTING ACTIVITIES</b>                                                               |                          |               |
| Purchases of items of property, plant and equipment                                                       | (10,036)                 | (7,826)       |
| Purchases of intangible assets                                                                            | (36,111)                 | (24,933)      |
| Placement of time deposits with original maturity over three months                                       | (300,000)                | –             |
| Proceeds from disposal of items of property, plant and equipment                                          | 4                        | 36            |
| Net cash flows used in investing activities                                                               | (346,143)                | (32,723)      |
| <b>CASH FLOWS FROM FINANCING ACTIVITIES</b>                                                               |                          |               |
| New bank borrowings                                                                                       | 95,300                   | 120,200       |
| Repayment of bank borrowings                                                                              | (78,008)                 | (79,257)      |
| Principal portion of lease payments                                                                       | (931)                    | –             |
| Interest paid                                                                                             | (2,532)                  | (3,723)       |
| Payment of listing expenses                                                                               | (83)                     | (6,368)       |
| Dividend paid                                                                                             | (1,560)                  | –             |
| Net cash flows from financing activities                                                                  | 12,186                   | 30,852        |
| <b>NET DECREASE IN CASH AND CASH EQUIVALENTS</b>                                                          | (321,439)                | (14,408)      |
| Cash and cash equivalents at beginning of period                                                          | 537,629                  | 93,178        |
| Effect of foreign exchange rate changes, net                                                              | 1,380                    | –             |
| <b>CASH AND CASH EQUIVALENTS AT END OF PERIOD</b>                                                         | <b>217,570</b>           | <b>78,770</b> |
| <b>ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS</b>                                                  |                          |               |
| Cash and cash equivalents as stated in the interim condensed consolidated statement of financial position | 217,570                  | 78,770        |
| Cash and cash equivalents as stated in the interim condensed consolidated statement of cash flows         | 217,570                  | 78,770        |

# Notes to Interim Condensed Consolidated Financial Information

## 1. BASIS OF PREPARATION

The interim condensed consolidated financial information for the six months ended 30 June 2025 has been prepared in accordance with HKAS 34 Interim Financial Reporting. The interim condensed consolidated financial information does not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual consolidated financial statements for the year ended 31 December 2024.

## 2. CHANGES IN ACCOUNTING POLICIES

The accounting policies adopted in the preparation of the interim condensed consolidated financial information are consistent with those applied in the preparation of the Group's annual consolidated financial statements for the year ended 31 December 2024, except for the adoption of the following amended HKFRS Accounting Standard for the first time for the current period's financial information.

Amendments to HKAS 21

*Lack of Exchangeability*

The nature and impact of the amended HKFRS Accounting Standard are described below:

Amendments to HKAS 21 specify how an entity shall assess whether a currency is exchangeable into another currency and how it shall estimate a spot exchange rate at a measurement date when exchangeability is lacking. The amendments require disclosures of information that enable users of financial statements to understand the impact of a currency not being exchangeable. As the currencies that the Group had transacted with and the functional currencies of group entities for translation into the Group's presentation currency were exchangeable, the amendments did not have any impact on the interim condensed consolidated financial information.

## 3. OPERATING SEGMENT INFORMATION

For management purposes, the Group is not organised into business units based on their services and only has one reportable operating segment. Management monitors the operating results of the Group's operating segment as a whole for the purpose of making decisions about resource allocation and performance assessment.

### Geographical information

#### (a) Revenue from external customers

|                         | For the six months ended 30 June |                              |
|-------------------------|----------------------------------|------------------------------|
|                         | 2025<br>RMB'000<br>(Unaudited)   | 2024<br>RMB'000<br>(Audited) |
| Mainland China          | 613,541                          | 671,829                      |
| Other countries/regions | 25,237                           | 30,531                       |
| Total revenue           | 638,778                          | 702,360                      |

The revenue information above is based on the locations of the customers.

# Notes to Interim Condensed Consolidated Financial Information

## 3. OPERATING SEGMENT INFORMATION (continued)

### Geographical information (continued)

#### (b) Non-current assets

|                | 30 June<br>2025<br>RMB'000<br>(Unaudited) | 31 December<br>2024<br>RMB'000<br>(Audited) |
|----------------|-------------------------------------------|---------------------------------------------|
| Mainland China | 588,469                                   | 513,048                                     |

The non-current asset information above is based on the locations of the assets and excludes financial instruments and deferred tax assets.

### Information about major customers

Revenue from the major customers (aggregated if under common control) which amounted to 10% or more of the Group's revenue is set out below:

|            | For the six months<br>ended 30 June<br>2025<br>RMB'000<br>(Unaudited) | 2024<br>RMB'000<br>(Audited) |
|------------|-----------------------------------------------------------------------|------------------------------|
| Customer A | 160,559                                                               | 151,760                      |
| Customer B | 29,935                                                                | 81,186                       |
| Total      | 190,494                                                               | 232,946                      |

## 4. REVENUE

An analysis of revenue is as follows:

|                                       | For the six months<br>ended 30 June<br>2025<br>RMB'000<br>(Unaudited) | 2024<br>RMB'000<br>(Audited) |
|---------------------------------------|-----------------------------------------------------------------------|------------------------------|
| Revenue from contracts with customers | 638,778                                                               | 702,360                      |

# Notes to Interim Condensed Consolidated Financial Information

## 4. REVENUE (continued)

Revenue from contracts with customers

Disaggregated revenue information

|                                      | For the six months<br>ended 30 June |                              |
|--------------------------------------|-------------------------------------|------------------------------|
|                                      | 2025<br>RMB'000<br>(Unaudited)      | 2024<br>RMB'000<br>(Audited) |
| <b>Types of goods or services</b>    |                                     |                              |
| Sale of goods                        | 621,789                             | 645,163                      |
| Pharmaceutical services              | 16,989                              | 57,197                       |
| Total                                | 638,778                             | 702,360                      |
| <b>Geographical markets</b>          |                                     |                              |
| Mainland China                       | 613,541                             | 671,829                      |
| Other countries/regions              | 25,237                              | 30,531                       |
| Total                                | 638,778                             | 702,360                      |
| <b>Timing of revenue recognition</b> |                                     |                              |
| Transferred at a point in time       | 638,778                             | 702,360                      |

# Notes to Interim Condensed Consolidated Financial Information

## 5. PROFIT BEFORE TAX

The Group's profit before tax is arrived at after charging/(crediting):

|                                                                     | For the six months<br>ended 30 June |                              |
|---------------------------------------------------------------------|-------------------------------------|------------------------------|
|                                                                     | 2025<br>RMB'000<br>(Unaudited)      | 2024<br>RMB'000<br>(Audited) |
| Cost of inventories sold                                            | 104,578                             | 131,595                      |
| Cost of services provided                                           | 8,981                               | 30,205                       |
|                                                                     | 113,559                             | 161,800                      |
| Research and development costs                                      | 49,627                              | 37,288                       |
| Depreciation of property, plant and equipment                       | 18,350                              | 17,481                       |
| Depreciation of right-of-use assets                                 | 706                                 | 418                          |
| Amortisation of intangible assets                                   | 3,407                               | 294                          |
| Loss on disposal of items of property, plant and equipment          | 8                                   | 107                          |
| Write-down of inventories to net realisable value                   | 1,029                               | 6,310                        |
| Impairment losses on financial assets, net                          | 8,857                               | 2,999                        |
| Lease payments not included in the measurement of lease liabilities | 650                                 | 504                          |
| Foreign exchange differences, net                                   | (1,380)                             | –                            |
| Listing expenses                                                    | –                                   | 9,926                        |
| Bank interest income                                                | (7,757)                             | (138)                        |
| Government grants                                                   | (6,695)                             | (9,025)                      |

# Notes to Interim Condensed Consolidated Financial Information

## 6. INCOME TAX

The Group is subject to income tax on an entity basis on profits arising in or derived from the jurisdictions in which members of the Group are domiciled and operate.

Under the Law of the PRC on Enterprise Income Tax (the “EIT Law”) and Implementation Regulation of the EIT Law, the EIT rate of the PRC subsidiary was 25% during the reporting period. The Company was accredited as a “High and New Technology Enterprise” (“HNTE”) in 2021 and the certificate was extended in December 2023. Therefore, the Company was entitled to a preferential EIT rate of 15% for the reporting period. The qualification as a HNTE is subject to review by the relevant tax authority in the PRC every three years.

The income tax charge/(credit) of the Group during the reporting period is analysed as follows:

|                              | <b>For the six months<br/>ended 30 June</b> |           |
|------------------------------|---------------------------------------------|-----------|
|                              | <b>2025</b>                                 | 2024      |
|                              | <b>RMB'000</b>                              | RMB'000   |
|                              | <b>(Unaudited)</b>                          | (Audited) |
| Current tax – Mainland China |                                             |           |
| Charge for the period        | <b>15,451</b>                               | 26,164    |
| Deferred tax                 | <b>(1,362)</b>                              | (1,679)   |
| Total tax charge             | <b>14,089</b>                               | 24,485    |

## 7. DIVIDENDS

On 26 March 2025, the board of directors of the Company approved the final dividend of the Company for 2024, agreeing to declare a cash dividend in the amount of RMB0.56 (tax inclusive) for every ten shares. The total amount of the cash dividend for 2024 was RMB13.7 million (tax inclusive). On 11 June 2025, the above final dividend was approved by the shareholders of the Company at the annual general meeting.

No interim dividend has been declared by the Company during the reporting period.

# Notes to Interim Condensed Consolidated Financial Information

## 8. EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

The calculation of the basic earnings per share amount is based on the profit for the period attributable to ordinary equity holders of the parent, and the weighted average number of ordinary shares of 245,398,800 (2024: 200,000,000) outstanding during the period.

The weighted average number of ordinary shares used in the calculation is the number of ordinary shares outstanding during the period, as used in the basic earnings per share calculation.

The Group had no potentially dilutive ordinary shares outstanding during the periods ended 30 June 2025 and 2024.

The calculations of basic and diluted earnings per share are based on:

|                                                                                                                                       | For the six months ended 30 June |             |
|---------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-------------|
|                                                                                                                                       | 2025                             | 2024        |
|                                                                                                                                       | RMB'000                          | RMB'000     |
|                                                                                                                                       | (Unaudited)                      | (Audited)   |
| <b>Earnings</b>                                                                                                                       |                                  |             |
| Profit attributable to ordinary equity holders of the parent, used in the basic and diluted earnings per share calculation            | 90,174                           | 105,348     |
| <b>Shares</b>                                                                                                                         |                                  |             |
| Weighted average number of ordinary shares outstanding during the period used in the basic and diluted earnings per share calculation | 245,398,800                      | 200,000,000 |
| Earnings per share (RMB per share)                                                                                                    | 0.37                             | 0.53        |

## 9. PROPERTY, PLANT AND EQUIPMENT

During the six months ended 30 June 2025, the Group acquired property, plant and equipment at a cost of RMB7,090,000 (30 June 2024: RMB8,443,000).

Assets with a net book value of RMB1,895,000 were disposed of by the Group during the six months ended 30 June 2025 (30 June 2024: RMB143,000).

# Notes to Interim Condensed Consolidated Financial Information

## 10. TRADE AND BILLS RECEIVABLES

|                                                                   | 30 June<br>2025<br>RMB'000<br>(Unaudited) | 31 December<br>2024<br>RMB'000<br>(Audited) |
|-------------------------------------------------------------------|-------------------------------------------|---------------------------------------------|
| Trade receivables                                                 | 649,056                                   | 594,344                                     |
| Bills receivable                                                  | 11,829                                    | 11,422                                      |
| Financial assets at fair value through other comprehensive income | 69,098                                    | 73,754                                      |
| Impairment                                                        | (9,648)                                   | (7,342)                                     |
| Net carrying amount                                               | 720,335                                   | 672,178                                     |

An ageing analysis of the trade and bills receivables of the Group as at the end of the reporting period, based on the invoice date and net of loss allowance, is as follows:

|               | 30 June<br>2025<br>RMB'000<br>(Unaudited) | 31 December<br>2024<br>RMB'000<br>(Audited) |
|---------------|-------------------------------------------|---------------------------------------------|
| Within 1 year | 651,532                                   | 628,980                                     |
| 1 to 2 years  | 63,793                                    | 40,455                                      |
| 2 to 3 years  | 3,772                                     | 2,511                                       |
| Over 3 years  | 1,238                                     | 232                                         |
| Total         | 720,335                                   | 672,178                                     |

## 11. TRADE PAYABLES

An ageing analysis of the trade payables as at the end of the reporting period, based on the invoice date, is as follows:

|               | 30 June<br>2025<br>RMB'000<br>(Unaudited) | 31 December<br>2024<br>RMB'000<br>(Audited) |
|---------------|-------------------------------------------|---------------------------------------------|
| Within 1 year | 35,132                                    | 26,988                                      |
| Over 1 year   | 250                                       | 12                                          |
| Total         | 35,382                                    | 27,000                                      |

The trade payables are non-interest-bearing and are normally settled within 60 days.

# Notes to Interim Condensed Consolidated Financial Information

## 12. SHARE CAPITAL

|                       | 30 June<br>2025<br>RMB'000<br>(Unaudited) | 31 December<br>2024<br>RMB'000<br>(Audited) |
|-----------------------|-------------------------------------------|---------------------------------------------|
| Issued and fully paid | 245,399                                   | 245,399                                     |

A summary of movements in the Company's share capital is as follows:

|                                                            | Number of<br>shares<br>outstanding | Share<br>capital<br>RMB'000 |
|------------------------------------------------------------|------------------------------------|-----------------------------|
| At 1 January 2024 (audited)                                | 200,000,000                        | 200,000                     |
| Shares issued upon the Initial Public Offering ("IPO")*    | 45,398,800                         | 45,399                      |
| At 31 December 2024 (audited) and 30 June 2025 (unaudited) | 245,398,800                        | 245,399                     |

\* On 28 November 2024, the Company successfully completed its IPO on the Main Board of The Stock Exchange of Hong Kong Limited, issuing 45,398,800 shares and the par value of each share is RMB1.00.

## 13. COMMITMENTS

The Group had the following contracted commitments at the end of the reporting period:

|                               | 30 June<br>2025<br>RMB'000<br>(Unaudited) | 31 December<br>2024<br>RMB'000<br>(Audited) |
|-------------------------------|-------------------------------------------|---------------------------------------------|
| Property, plant and equipment | 7,364                                     | 1,839                                       |

# Notes to Interim Condensed Consolidated Financial Information

## 14. RELATED PARTY TRANSACTIONS

(a) The Group had the following transactions with related parties during the period:

|                                                                     |       | For the six months<br>ended 30 June |           |
|---------------------------------------------------------------------|-------|-------------------------------------|-----------|
|                                                                     |       | 2025                                | 2024      |
|                                                                     |       | RMB'000                             | RMB'000   |
|                                                                     |       | (Unaudited)                         | (Audited) |
| Shareholder:                                                        |       |                                     |           |
| Pharmaceutical services                                             | (i)   | 7,935                               | 57,056    |
| The holding company of a shareholder:                               |       |                                     |           |
| Sales of products                                                   | (iii) | 19,827                              | 21,700    |
| Purchases of raw materials                                          | (iii) | 1,229                               | 2,486     |
| Purchases of devices                                                | (iii) | 161                                 | 834       |
| Rental charges                                                      | (ii)  | 64                                  | 64        |
| The entities controlled by the holding company<br>of a shareholder: |       |                                     |           |
| Sales of products                                                   | (iii) | 2,173                               | 2,430     |

Notes:

- (i) The pharmaceutical services provided to the shareholder were conducted according to the agreed prices and conditions offered to the major customers of the Group.
- (ii) The rental charges with the holding company of a shareholder were made according to the agreed prices.
- (iii) The purchases from and sales to the related parties were made according to the agreed prices between the Group and its major customers and suppliers.

# Notes to Interim Condensed Consolidated Financial Information

## 14. RELATED PARTY TRANSACTIONS (continued)

### (b) Outstanding balances with related parties

|                                                                 | 30 June<br>2025<br>RMB'000<br>(Unaudited) | 31 December<br>2024<br>RMB'000<br>(Audited) |
|-----------------------------------------------------------------|-------------------------------------------|---------------------------------------------|
| Due to related parties:                                         |                                           |                                             |
| The holding company of a shareholder                            | 1,032                                     | 644                                         |
| Due from related parties:                                       |                                           |                                             |
| Shareholders                                                    | 25,108                                    | 25,498                                      |
| The holding company of a shareholder                            | 10,764                                    | 8,661                                       |
| The entities controlled by the holding company of a shareholder | 2,940                                     | 3,215                                       |
| Total                                                           | 38,812                                    | 37,374                                      |

Note:

The above balances with related parties are trade-in-nature, unsecured and interest-free.

### (c) Compensation of key management personnel of the Group

|                                                     | For the six months<br>ended 30 June<br>2025<br>RMB'000<br>(Unaudited) | 2024<br>RMB'000<br>(Audited) |
|-----------------------------------------------------|-----------------------------------------------------------------------|------------------------------|
| Salaries, allowances and benefits in kind           | 3,361                                                                 | 3,118                        |
| Performance related bonuses                         | 1,947                                                                 | 1,531                        |
| Pension scheme contributions                        | 215                                                                   | 188                          |
| Equity-settled share award expense                  | 1,668                                                                 | 1,772                        |
| Total compensation paid to key management personnel | 7,191                                                                 | 6,609                        |

# Notes to Interim Condensed Consolidated Financial Information

## 15. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS

The carrying amounts and fair values of the Group's financial instruments, other than those with carrying amounts that reasonably approximate to fair values, are as follows:

|                                  | Carrying amounts                          |                                             | Fair values                               |                                             |
|----------------------------------|-------------------------------------------|---------------------------------------------|-------------------------------------------|---------------------------------------------|
|                                  | 30 June<br>2025<br>RMB'000<br>(Unaudited) | 31 December<br>2024<br>RMB'000<br>(Audited) | 30 June<br>2025<br>RMB'000<br>(Unaudited) | 31 December<br>2024<br>RMB'000<br>(Audited) |
| <b>Financial liabilities</b>     |                                           |                                             |                                           |                                             |
| Interest-bearing bank borrowings | 137,064                                   | 119,783                                     | 138,083                                   | 120,970                                     |

The fair values of the non-current portion of interest-bearing bank loans have been calculated by discounting the expected future cash flows using rates currently available for instruments with similar terms, credit risk and remaining maturities.

Management has assessed that the fair values of cash and cash equivalents, financial assets included in prepayments, other receivables and other assets, amount due from related parties, trade and bills receivables, trade payables, the current portion of interest-bearing bank borrowings, amount due to related parties and financial liabilities included in other payables and accruals approximate to their carrying amounts largely due to the short-term maturities of these instruments.

The Group's finance department headed by the financial controller is responsible for determining the policies and procedures for the fair value measurement of financial instruments. The finance department reports directly to the financial controller. At the reporting date, the finance department analyses the movements in the values of financial instruments and determines the major inputs applied in the valuation. The valuation is reviewed and approved by the financial controller. The valuation process and results are discussed with the directors of the Company periodically for financial reporting.

The fair values of the financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale. The following methods and assumptions were used to estimate the fair values.

The fair value of those not traded in an active market is determined by the Group using valuation techniques. The valuation model used is discounted cash flow model. The input of the valuation technique is future cash flows.

# Notes to Interim Condensed Consolidated Financial Information

## 15. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (continued)

### Fair value hierarchy

The following tables illustrate the fair value measurement hierarchy of the Group's financial instruments:

#### Assets measured at fair value:

As at 30 June 2025 (unaudited)

|                             | Fair value measurement using                                  |                                                             |                                                               | Total<br>RMB'000 |
|-----------------------------|---------------------------------------------------------------|-------------------------------------------------------------|---------------------------------------------------------------|------------------|
|                             | Quoted prices<br>in active<br>markets<br>(Level 1)<br>RMB'000 | Significant<br>observable<br>inputs<br>(Level 2)<br>RMB'000 | Significant<br>unobservable<br>inputs<br>(Level 3)<br>RMB'000 |                  |
| Trade and bills receivables | –                                                             | 69,098                                                      | –                                                             | 69,098           |

As at 31 December 2024 (audited)

|                             | Fair value measurement using                                  |                                                             |                                                               | Total<br>RMB'000 |
|-----------------------------|---------------------------------------------------------------|-------------------------------------------------------------|---------------------------------------------------------------|------------------|
|                             | Quoted prices<br>in active<br>markets<br>(Level 1)<br>RMB'000 | Significant<br>observable<br>inputs<br>(Level 2)<br>RMB'000 | Significant<br>unobservable<br>inputs<br>(Level 3)<br>RMB'000 |                  |
| Trade and bills receivables | –                                                             | 73,754                                                      | –                                                             | 73,754           |

# Notes to Interim Condensed Consolidated Financial Information

## 15. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (continued)

### Fair value hierarchy (continued)

The following tables illustrate the fair value measurement hierarchy of the Group's financial instruments: (continued)

#### Liabilities for which fair value is disclosed:

##### As at 30 June 2025 (unaudited)

|                                  | Fair value measurement using                                  |                                                             |                                                               | Total<br>RMB'000 |
|----------------------------------|---------------------------------------------------------------|-------------------------------------------------------------|---------------------------------------------------------------|------------------|
|                                  | Quoted prices<br>in active<br>markets<br>(Level 1)<br>RMB'000 | Significant<br>observable<br>inputs<br>(Level 2)<br>RMB'000 | Significant<br>unobservable<br>inputs<br>(Level 3)<br>RMB'000 |                  |
| Interest-bearing bank borrowings | –                                                             | 138,083                                                     | –                                                             | 138,083          |

##### As at 31 December 2024 (audited)

|                                  | Fair value measurement using                                  |                                                             |                                                               | Total<br>RMB'000 |
|----------------------------------|---------------------------------------------------------------|-------------------------------------------------------------|---------------------------------------------------------------|------------------|
|                                  | Quoted prices<br>in active<br>markets<br>(Level 1)<br>RMB'000 | Significant<br>observable<br>inputs<br>(Level 2)<br>RMB'000 | Significant<br>unobservable<br>inputs<br>(Level 3)<br>RMB'000 |                  |
| Interest-bearing bank borrowings | –                                                             | 120,970                                                     | –                                                             | 120,970          |

During the reporting period, there were no transfers of fair value measurements between Level 1 and Level 2 and no transfers into or out of Level 3 for both financial assets and financial liabilities.

## 16. EVENTS AFTER THE REPORTING PERIOD

No significant events took place subsequent to 30 June 2025.